West Oak Capital’s Royalty Pharma RPRX Stock Holding History

West Oak Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25	Closed	-$1K	–	359
2022 Q1	$1K	Hold	25	–	–	﹤0.01%	343
2021 Q4	$1K	Buy	+25	New	+$971	﹤0.01%	346

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

West Oak Capital's RPRX Position: Q2 2022 in Review

West Oak Capital sold out of Royalty Pharma (RPRX) in Q2 2022, closing a stake of 25 shares — an estimated $1K sold.

West Oak Capital first reported a position in RPRX in Q4 2021 and held it in 2 quarters. The position peaked at $1K in Q1 2022. 283 funds tracked by Wall St. Rank hold RPRX as of Q2 2022.

West Oak Capital reported no remaining Royalty Pharma position as of Q2 2022 after selling out during the quarter.
West Oak Capital sold 25 Royalty Pharma shares in Q2 2022, an estimated $1K.
West Oak Capital first reported a position in Royalty Pharma in Q4 2021 and held it in 2 quarters.
West Oak Capital's Royalty Pharma position peaked at $1K in Q1 2022.
283 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2022.

Based on West Oak Capital's 13F filing for Q2 2022, filed 11 Jul 2022.